Henipaviruses (HNVs), including Nipah virus (NiV) and Hendra virus (HeV), are zoonotic paramyxoviruses with high case fatality rates and pandemic potential. Despite their threat, no licensed vaccines are currently available for human use. Here, we present a structure-guided mRNA vaccine strategy that overcomes key challenges in antigen stability, fusogenicity, and cross-protective efficacy. Using rationally engineered NiV F glycoproteins stabili…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.